Efficacy of Two Daily - Use CHX Based Mouth Rinses on Microbial Biofilm Accumulation, Gingivitis Development, and Staining

Overview

Τhe aim of this randomized clinical trial was to investigate the efficacy of two daily mouth rinses containing CHX and different combinations of H2O2 and CPC, when used adjunctive to mechanical oral hygiene, and compare them with a placebo mouth rinse. The primary outcomes evaluated were changes in i) bacterial biofilm accumulation, ii) gingival inflammation, and iii) tooth staining. Secondarily, patient's satisfaction and perspective after the use of these formulations was assessed.

Trial design: This is a single-center, randomized, controlled, double-blind, parallel-design, 3- month clinical trial that compares the effectiveness of two different mouth rinses: 1) CHX 0.05% + CPC 0.05% + H2O2 0.8%, and 2) CHX 0.05% + CPC 0.05% with a placebο mouth rinse containing the same color as CHX mouth rinses but without antimicrobial agents. Experimental phases: Following patient screening and selection, individuals received written details about the products and the research objectives, and those who volunteered for the study signed a consent form. All participants underwent scaling, air polishing, and received oral hygiene instructions. Patients were instructed to abstained from using any oral rinses for the following two weeks until they entered the trial. The aim of this preparatory phase was to allow only participants with low PI and GI scores (\<15%) to take part in the clinical trial. Individuals with PI and GI ≥ 15% were re-enrolled in the two-weeks preparation phase and were reevaluated for suitability to participate in the trial. After the preparatory phase, baseline (V0) measurements of PI, GI and stain index (SI) were recorded, and subjects were randomly allocated in one of the three following groups based on the different mouth rinse they received to use: Group 1: CHX 0.05%+ CPC 0.05% + H2O2 0.8%. Group 2: CHX 0.05% + CPC 0.05% Group 3: Placebo As a double-blind clinical study, neither the periodontist nor the participants are aware of the actual assigned treatment. In case of immediate unblinding of the patient (e.g., serious adverse events), the researcher has obtained opaque identical envelopes containing information regarding the treatment group to which the participant belongs. In the event of unblinding, the date/time and reason for unblinding are recorded in the research database. All participants were instructed to rinse for 3 months for 1 minute twice a day with 15 ml of the provided solution. They were also instructed to refrain from eating or drinking for at least half an hour after rinsing, and to avoid intake of more than two glasses of coffee, tea or red wine daily. The oral rinses were placed in opaque plastic containers of the same color, and with a capacity of 1500 ml. The containers were pre-labeled with the individual patient's serial number, so that both the patients and the examiner were unaware of which of the three oral rinses was being used each time. At the 1-month (V1), 2-months (V2) and 3-months (V3) re-evaluation, PI, GI, and SI, were recorded as described below. In addition, the examiner monitored for potential side effects, and weighed the containers to evaluate patient's compliance. At the end of the trial a questionnaire was given to the participants to assess the patient's perspective on possible secondary effects, such as taste alteration, staining, burning feeling, and irritation. Clinical measurements All measurements were performed by the same examiner (periodontist), who was unaware of the group allocation. The following clinical parameters were evaluated: * PI (Turesky et al. (1970) modification of the Quigley and Hein index (1962)) * Percentages of dental surface covered by dental plaque (PA%) (Pretty et al., 2005, Sagel et al., 2000). * GI (Löe and Silness (1963)) * SI (Lobene (1968)) * Time of professional mechanical removal at V3 Questionnaire Patients' perception of the product and possible adverse effects were registered in the questionnaire patients had to fill in, in the last visit, by placing a mark in a 10 cm visual analog scale (VAS). (García-Gargallo et al.2017)